×
Zoetis Basic EPS 2011-2024 | ZTS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Zoetis basic eps for the twelve months ending December 31, 2024 was
$5.58
, a
4.1% increase
year-over-year.
Zoetis annual basic eps for 2024 was
$0.005B
, a
0% decline
from 2024.
Zoetis annual basic eps for 2024 was
$0.005B
, a
7.68% increase
from 2023.
Zoetis annual basic eps for 2023 was
$0.005B
, a
0% decline
from 2023.
View More
Zoetis Basic EPS 2011-2024 | ZTS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Zoetis annual basic eps for 2024 was
$0.005B
, a
0% decline
from 2024.
Zoetis annual basic eps for 2024 was
$0.005B
, a
7.68% increase
from 2023.
Zoetis annual basic eps for 2023 was
$0.005B
, a
0% decline
from 2023.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$79.9B
Daiichi Sankyo, - (DSNKY)
$43.9B
Takeda Pharmaceutical (TAK)
$43.7B
Sandoz Group AG (SDZNY)
$20.6B
Merck (MKKGY)
$18.3B
Astellas Pharma (ALPMY)
$17.4B
United Therapeutics (UTHR)
$17B
Summit Therapeutics (SMMT)
$15.9B
Shionogi (SGIOY)
$12.3B
Neurocrine Biosciences (NBIX)
$11.4B
Corcept Therapeutics (CORT)
$7.7B
Madrigal Pharmaceuticals (MDGL)
$7.5B
Orion OYJ (ORINY)
$7.4B
Hikma Pharmaceuticals Plc (HKMPF)
$6.2B
Stevanato Group S.p.A (STVN)
$6.2B
Grifols, S.A (GRFS)
$5.1B
Ionis Pharmaceuticals (IONS)
$5B
Ono Pharmaceutical (OPHLF)
$4.7B
Recursion Pharmaceuticals (RXRX)
$4.2B
Crinetics Pharmaceuticals (CRNX)
$3.4B
Catalyst Pharmaceuticals (CPRX)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.4B
Hypermarcas (HYPMY)
$2.2B
Centessa Pharmaceuticals (CNTA)
$2.1B
Soleno Therapeutics (SLNO)
$2B
BioCryst Pharmaceuticals (BCRX)
$1.9B
NewAmsterdam Pharma (NAMS)
$1.8B
Evotec AG (EVO)
$1.6B
Ardelyx (ARDX)
$1.5B
Indivior (INDV)
$1.5B